Literature DB >> 34353699

Low-density lipoprotein cholesterol levels are associated with poor clinical outcomes in COVID-19.

Álvaro Aparisi1, Carolina Iglesias-Echeverría1, Cristina Ybarra-Falcón1, Iván Cusácovich2, Aitor Uribarri1, Mario García-Gómez1, Raquel Ladrón1, Raúl Fuertes3, Jordi Candela1, Javier Tobar1, Williams Hinojosa1, Carlos Dueñas2, Roberto González2, Leonor Nogales4, Dolores Calvo5, Manuel Carrasco-Moraleja1, J Alberto San Román6, Ignacio J Amat-Santos6, David Andaluz-Ojeda7.   

Abstract

BACKGROUND AND AIMS: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the sole causative agent of coronavirus infectious disease-19 (COVID-19). METHODS AND
RESULTS: We performed a retrospective single-center study of consecutively admitted patients between March 1st and May 15th, 2020, with a definitive diagnosis of SARS-CoV-2 infection. The primary end-point was to evaluate the association of lipid markers with 30-days all-cause mortality in COVID-19. A total of 654 patients were enrolled, with an estimated 30-day mortality of 22.8% (149 patients). Non-survivors had lower total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-c) levels during the entire course of the disease. Both showed a significant inverse correlation with inflammatory markers and a positive correlation with lymphocyte count. In a multivariate analysis, LDL-c ≤ 69 mg/dl (hazard ratio [HR] 1.94; 95% confidence interval [CI] 1.14-3.31), C-reactive protein >88 mg/dl (HR 2.44; 95% CI, 1.41-4.23) and lymphopenia <1000 (HR 2.68; 95% CI, 1.91-3.78) at admission were independently associated with 30-day mortality. This association was maintained 7 days after admission. Survivors presented with complete normalization of their lipid profiles on short-term follow-up.
CONCLUSION: Hypolipidemia in SARS-CoV-2 infection may be secondary to an immune-inflammatory response, with complete recovery in survivors. Low LDL-c serum levels are independently associated with higher 30-day mortality in COVID-19 patients.
Copyright © 2021 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  COVID-19; Coronavirus; High-density lipoprotein; Inflammation; Low-density lipoprotein; SARS-CoV-2; Total cholesterol; Triglycerides

Year:  2021        PMID: 34353699     DOI: 10.1016/j.numecd.2021.06.016

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  7 in total

1.  Thyroid-Stimulating Hormone Predicts Total Cholesterol and Low-Density Lipoprotein Cholesterol Reduction during the Acute Phase of COVID-19.

Authors:  Massimo Raffaele Mannarino; Vanessa Bianconi; Elena Cosentini; Filippo Figorilli; Cecilia Colangelo; Francesco Giglioni; Rita Lombardini; Rita Paltriccia; Matteo Pirro
Journal:  J Clin Med       Date:  2022-06-10       Impact factor: 4.964

2.  Remnant cholesterol levels are associated with severity and death in COVID-19 patients.

Authors:  Bibiana Fabre; Nahuel Fernandez Machulsky; Carolina Olano; Darío Jacobsen; María Eugenia Gómez; Beatriz Perazzi; Valeria Zago; Damián Zopatti; Andrés Ferrero; Laura Schreier; Gabriela Berg
Journal:  Sci Rep       Date:  2022-10-20       Impact factor: 4.996

3.  Strong relationship between cholesterol, low-density lipoprotein receptor, Na+/H+ exchanger, and SARS-COV-2: this association may be the cause of death in the patient with COVID-19.

Authors:  Erkan Cure; Medine Cumhur Cure
Journal:  Lipids Health Dis       Date:  2021-12-13       Impact factor: 3.876

4.  First Recombinant High-Density Lipoprotein Particles Administration in a Severe ICU COVID-19 Patient, a Multi-Omics Exploratory Investigation.

Authors:  Sébastien Tanaka; Floran Begue; Bryan Veeren; Alexy Tran-Dinh; Tiphaine Robert; Parvine Tashk; Brice Lortat-Jacob; Dorothée Faille; Luc de Chaisemartin; Nathalie Zappella; Enora Atchade; Laura Kramer; Philippe Montravers; Olivier Meilhac
Journal:  Biomedicines       Date:  2022-03-23

5.  Investigation of systemic immune-inflammation index, neutrophil/high-density lipoprotein ratio, lymphocyte/high-density lipoprotein ratio, and monocyte/high-density lipoprotein ratio as indicators of inflammation in patients with schizophrenia and bipolar disorder.

Authors:  Yanyan Wei; Tingting Wang; Guoguang Li; Junhui Feng; Lianbang Deng; Haiting Xu; Lu Yin; Jinbao Ma; Dongning Chen; Jingxu Chen
Journal:  Front Psychiatry       Date:  2022-07-26       Impact factor: 5.435

6.  MAGI1 inhibits interferon signaling to promote influenza A infection.

Authors:  Yin Wang; Jun-Ichi Abe; Khanh M Chau; Yongxing Wang; Hang Thi Vu; Loka Reddy Velatooru; Fahad Gulraiz; Masaki Imanishi; Venkata S K Samanthapudi; Minh T H Nguyen; Kyung Ae Ko; Ling-Ling Lee; Tamlyn N Thomas; Elizabeth A Olmsted-Davis; Sivareddy Kotla; Keigi Fujiwara; John P Cooke; Di Zhao; Scott E Evans; Nhat-Tu Le
Journal:  Front Cardiovasc Med       Date:  2022-08-23

Review 7.  A Review of Routine Laboratory Biomarkers for the Detection of Severe COVID-19 Disease.

Authors:  Keynaz Keykavousi; Fahimeh Nourbakhsh; Nooshin Abdollahpour; Farzaneh Fazeli; Alireza Sedaghat; Vahid Soheili; Amirhossein Sahebkar
Journal:  Int J Anal Chem       Date:  2022-10-11       Impact factor: 1.698

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.